Salemonline Journal

“The Hepatic Encephalopathy Market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Hepatic Encephalopathy pipeline products will significantly revolutionize the Hepatic Encephalopathy market dynamics”

The Hepatic Encephalopathy market report provides current treatment practices, Hepatic Encephalopathy emerging drugs, market share of individual therapies, and current and forecasted 7MM Hepatic Encephalopathy market size from 2019 to 2032. The report also covers current Hepatic Encephalopathy treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Key Takeaways from the Hepatic Encephalopathy Market Research Report

• The increase in Hepatic Encephalopathy market size is a direct consequence of expected approval of emerging therapies and increasing patient population of Hepatic Encephalopathy in the 7MM.
• According to DelveInsight analysis, out of the total diagnosed prevalent cases of Hepatic Encephalopathy, in the United States, 72.70% were occupied by males.
• The leading companies working in the Hepatic Encephalopathy Market include Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix and others.
• Promising Hepatic Encephalopathy Pipeline Therapies in the various stages of development include Rifaximin, 40 mg Rifaximin SSD once daily, AST-120, lactulose, ornithine phenylacetate, HPN-100, and others.
• April 2023: Bausch Health Americas Inc. announced a study of phase 2 Clinical Trials for 40 mg Rifaximin SSD once daily. Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE).
• April 2023: Ochsner Health System announced a study of phase 2 clinical trials for RBX7455. The purpose of this study is to determine if individuals with cirrhosis who experience hepatic encephalopathy would benefit from investigational microbiota restoration therapy due to their inherent cognitive alterations.

Discover more about therapies set to grab major Hepatic Encephalopathy Market Share @ Hepatic Encephalopathy Market Size

Hepatic Encephalopathy Overview

Hepatic encephalopathy (HE) is a brain disorder that develops in some individuals with liver disease. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease. It is observed in acute liver failure, liver bypass procedures – for example, shunt surgery and trans-jugular intrahepatic portosystemic shunt – and cirrhosis, classified as Type A, B, and C HE, respectively. Pathogenesis is linked with ammonia and glutamine production.

Hepatic Encephalopathy Epidemiology Segmentation in the 7MM

• Total Hepatic Encephalopathy Diagnosed Prevalent Cases
• Hepatic Encephalopathy Age-specific Diagnosed Prevalent Cases
• Hepatic Encephalopathy Gender-specific Diagnosed Prevalent Cases
• Hepatic Encephalopathy Type-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Hepatic Encephalopathy Epidemiology Trends @ Hepatic Encephalopathy Epidemiological Insights

Hepatic Encephalopathy Treatment Market

The treatment of acute or persistent HE has changed very little during the past 40 years. However, with newer agents under investigation, the available treatment options will increase over 5 years. Until then, treatment options are limited to correcting or removing precipitating causes, dietary changes, and pharmacologic approaches that are focused on the use of non-absorbable disaccharides. Additional pharmacological agents available include certain antibiotics, drugs to eliminate ammonia from the plasma, and a few other drugs with special indications.

Hepatic Encephalopathy Market Landscape

The overall market of Hepatic Encephalopathy is expected to boost due to rising prevalence of Hepatic Encephalopathy over the globe and thus the surge in treatment options. Along with these, expected launch of emerging therapies will boost the Hepatic Encephalopathy treatment market in the forecasted period (2023–2032).

To know more about Hepatic Encephalopathy Treatment options, visit @ Hepatic Encephalopathy Drugs

Hepatic Encephalopathy Emerging Therapy Assessment

Hepatic Encephalopathy pipeline possesses potential drugs in mid and late stage developments to be approved in the near future. The major key players include Salix Pharmaceuticals/Bausch Health, Vedanta Biosciences and several others hold the potential to create a significant positive shift in Hepatic Encephalopathy market size.

Learn more about the Hepatic Encephalopathy Pipeline Therapies in clinical trials @ Hepatic Encephalopathy Market Landscape

Scope of the Hepatic Encephalopathy Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Hepatic Encephalopathy Companies- Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix and others.
• Hepatic Encephalopathy Pipeline Therapies- Rifaximin, 40 mg Rifaximin SSD once daily, AST-120, lactulose, ornithine phenylacetate, HPN-100, and others.
• Hepatic Encephalopathy Market Dynamics: Hepatic Encephalopathy Market Drivers and Barriers
• Hepatic Encephalopathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Hepatic Encephalopathy Drugs in development @ Hepatic Encephalopathy Ongoing Clinical Trials Analysis

Table of Content

1. Key Insights

2. Hepatic Encephalopathy Report Introduction

3. Hepatic Encephalopathy Market Overview at a Glance

4. Hepatic Encephalopathy Market: Future Perspective

5. Executive Summary of Hepatic Encephalopathy

6. Key Events

7. Hepatic Encephalopathy Market Disease Background and Overview

8. Hepatic Encephalopathy Epidemiology and Patient Population

9. Patient Journey

10. Hepatic Encephalopathy Marketed Therapies

11. Hepatic Encephalopathy Emerging Drugs

12. Hepatic Encephalopathy: Seven Major Market Analysis

13. Hepatic Encephalopathy KOL Views

14. Hepatic Encephalopathy Market Drivers

15. Hepatic Encephalopathy Market Barriers

16. Hepatic Encephalopathy SWOT Analysis

17. Hepatic Encephalopathy Unmet Needs

18. Reimbursement and Market Access

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking